Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 14, 2026Investment Snapshot
- P/B of 212.49 — trading above book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -49.2%
- Revenue growing at 20% annually
Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $2.6 billion . Key value metrics: P/B ratio 212.49, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Ultragenyx Pharmaceutical Inc. - Common Stock — Fundamental Analysis Summary
On financial health, RARE shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -49.2% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 128.21.
StockPik's composite Value Score for RARE is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RARE shows revenue growing at 20% year-over-year, with earnings declining at 1%.